Photo: XinhuaChina's COVID-19 vaccine trial, the first such vaccine to reach phase 1 clinical trial, has been found to be safe, well-tolerated, and able to generate an immune response against SARS-COV-2 in humans, according to a study published online on Friday by medical journal The Lancet. Massive changes to California voting spark fears of Iowa-style primary chaosAsian Americans wait for their turn to shine in HollywoodCal's epidemic protection services still have room for improvement